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1. Background
1.1. Basic pharmacology and mechanisms of action
of ketamine
Ketamine is commonly used as an analgesic in emergency
medicine and as an adjuvant drug in the perioperative setting. In
addition, it is used as a third-line adjuvant drug for opioid-resistant
pain in palliative care and for intractable chronic noncancer pain.
More recently, ketamine is increasingly being used to treat major
depression and other mood disorders.
Ketamine is a phencyclidine derivative that was developed in
the 1960s as an anaesthetic agent. The most important
pharmacological properties of ketamine are due to it being
a noncompetitive N-methyl-D-aspartate (NMDA) receptor antag-
onist, and its analgesic action at subanaesthetic dose is believed
to be primarily due to NMDA receptor antagonism in the brain and
spinal cord.33 The NMDA receptor is important for learning,
memory, and synaptic plasticity. Regarding pain, the NMDA
receptor is involved in the amplification of pain signals, the
development of central sensitization, and opioid tolerance.49
Ketamine has been shown to have antihyperalgesic effects and to
reduce or reverse opioid tolerance.22,24
Ketamine also interacts with other receptors and channels,
including nicotinic andmuscarinic acetylcholine receptors, opioid
receptors, monoaminergic receptors, and voltage-sensitive
sodium channels.41 It enhances endogenous antinociceptive
systems, increasing the descending inhibitory serotoninergic
pathway.33 Recent research indicates that ketamine may also
modulate (suppress) pain transmission by limiting astrocyte and
microglial activation.46
Ketamine gives robust and rapid relief of major depression and
suicidal ideation.1 The mechanism for this effect is as yet not fully
elucidated, but major depressive disorder is associated with
synaptic downregulation in the prefrontal cortex and hippocam-
pus, and it is believed that ketamine causes a glutamate surge
that leads to a series of events resulting in synaptogenesis and
reversal of the negative effects of depression and chronic stress.1
A recent functional magnetic resonance imaging study in patients
with treatment-resistant depression compared with healthy
volunteers demonstrated that ketamine normalized depression-
related prefrontal dysconnectivity.2
Ketamine has anti-inflammatory effects, modulating the pro-
duction of different proinflammatory mediators. A recent study
using a rabbit model of gonarthrosis found that ketamine
suppressed the inflammatory response in osteoarthritis,28
whereas a systematic review concluded that intraoperative
ketamine reduces the postoperative IL-6 inflammatory response
in surgical patients.15
The most commonly reported adverse effects of ketamine are
psychotomimetic (hallucinations, agitation, anxiety, dysphoria,
and euphoria). Administration of ketamine may also cause
dizziness, nausea, sedation, and tachycardia. Ketamine’s
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Key Points
1. There is good evidence that perioperative ketamine
decreases postoperative pain scores and opioid require-
ments, but there is a lack of consensus on dose, for both
bolus and infusion.
2. Despite limited evidence, a trial of low-dose intravenous or
subcutaneous ketamine adjuvant to morphine may be
warranted in refractory cancer pain.
3. There is only very limited evidence for the use of ketamine
in chronic noncancer pain and concerns and a lack of
safety data concerning long-term or repeated treatment.
Importantly, there is no strong evidence to support the
current practice of treating chronic noncancer pain with
repeated intravenous infusions.
4. Ketamine has dose-dependent adverse effects, and there
are good arguments for avoiding high doses.
5. Spinal administration is associated with neurotoxicity,
whereas oral ketamine has low bioavailability and is
associated with adverse effects.
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adverse effects are dose-dependent. At low dose, it acts as an
NMDA receptor antagonist, providing an analgesic effect; but at
higher doses, it acts on other receptors and channels including
dopamine D2 receptors, monoaminergic receptors, and opioid
receptors.62 Ketamine dose dependently inhibits monoamine
transporters, and it has been suggested that this may be one
mechanism behind its psychotomimetic adverse effects.41
Chronic abuse of ketamine is associated with a range of adverse
effects, some of which have also been reported in pain patients
treated with ketamine (Tables 1 and 2).
1.2. Pharmacokinetics and administration of ketamine
Ketamine is available as a racemic mixture or as the S(1)
enantiomer that is approximately twice as potent as racemic
ketamine and about 4 times as potent as the R(2) enantiomer.33
Ketamine is N-demethylated by liver microsomes into the major
metabolite of racemic ketamine, norketamine, which is rapidly
metabolized to ketamine’s major secondary metabolite, 6-
hydroxynorketamine, and to the lesser metabolites 4-
hydroxyketamine and 6-hydroxyketamine.33 Ketamine has been
shown to have antinociceptive effects and to reduce opioid
tolerance, whereas norketamine has been shown to have
antinociceptive properties in animal studies, but little is known
about its analgesic effects in humans. A study in healthy
volunteers found that S(1)-norketamine after S(1) ketamine
dosing did not have significant antinociceptive properties and
even made a negative contribution to S(1) ketamine analgesia.39
Six-hydroxynorketamine in an animal model failed both to
demonstrate antinociceptive properties and to attenuate opioid
tolerance.26
Ketamine may be given by multiple routes of administration
including intravenous (IV), subcutaneous, oral, intranasal, trans-
dermal, and spinal (epidural and intrathecal). Spinal administration
of ketamine has been shown to be associated with neurotoxicity,
safety data are lacking and no NMDA receptor antagonists have
been approved for neuraxial use in humans.57 The oral bio-
availability of ketamine is low, reportedly 17% to 24% for oral
racemic ketamine and 8% to 11% for oral S(1)-ketamine.41 After
oral intake of ketamine, norketamine plasma concentrations are
much higher than those of the parent drug.41
Ketamine does not cause respiratory depression and does not
decrease blood pressure, making it a useful drug in emergency
medicine and intensive care, although there are certain concerns
because of its effect on intracranial pressure and ocular pressure.
The use of ketamine in emergency medicine and intensive care is
beyond the scope of this review.
Ketamine’s antihyperalgesic, antidepressant, and anti-
inflammatory effects, together with its beneficial interactions with
opioids, including reduction of opioid tolerance, make it an
especially interesting drug to use in pain management. However,
depending on the clinical setting, the extent to which ketamine is
clinically useful depends not only on its efficacy and tolerability but
also on other factors such as ease of administration, costs, and
long-term safety.
The best evidence for efficacy and tolerability comes from
systematic reviews of randomized controlled trials (RCTs), whereas
case reports provide valuable information onadverse effects. In this
review, we will examine the current evidence for the benefits and
harms of ketamine and its clinical usefulness in pain management.
2. Ketamine for acute postoperative pain
There is a large body of literature addressing the use of ketamine
in the perioperative setting. Adjuvant treatment with IV racemic, or
S(1) ketamine is common, to improve postoperative pain relief
and reduce opioid requirements. Epidural ketamine has also
been used in this setting. In some cases, ketamine has been used
with the aim of preventing chronic postoperative pain.
2.1. Evidence for efficacy and adverse effects
A search of PubMed on February 23, 2018, using the terms
“ketamine” AND “postoperative pain” and the filter “systematic
reviews” yielded 56 hits, 11 of which were systematic reviews
addressing perioperative ketamine for acute or chronic post-
operative pain4,8,16,21,30,36,42,55,59,60,63 (Table 3). A recently
completed Cochrane review,14 currently under review, has also
been included.
Perioperative ketamine decreased postoperative pain
scores,4,8,16,21,30,36,42,55,60,63 increased the time to first analgesic
request,21,60 and reduced postoperative opioid require-
ments.4,8,16,21,42,55,59,60,63 Ketamine also reduced postoperative
nausea and/or vomiting.4,21,36,55,60,63 Interestingly, Laskowski
et al.21 found that ketamine had significant analgesic benefit for
major procedures involving the upper abdomen and thorax,
Table 1
Adverse effects of ketamine, other than psychotomimetic, reported in cancer/palliative care pain management.
Adverse effect Authors Comment
Neurotoxicity (subpial vacuolar myelopathy) Karpinski et al., 199720 Intrathecal ketamine with preservative
(benzethonium chloride) 5 mg/d
Neurotoxicity (focal lymphocytic vasculitis in
medullary tissue, nerves, and leptomeninges of
the thoracic and lumbar spinal cord)
Stotz et al., 199948 Intrathecal ketamine with preservative
(benzethonium chloride), mean dose 67.2 mg/d
Neurotoxicity (severe histological abnormalities:
central chromatolysis, nerve cell shrinkage,
neuronophagia, microglial upregulation, and
gliosis)
Vranken et al., 200554 Intrathecal preservative-free S(1) ketamine 20–50
mg/d
Generalized hyperalgesia and allodynia Mitchell, 199934 After abrupt cessation of 3-wk subcutaneous
infusion 200 mg/24 h.
Urotoxicity Storr et al., 200947 Oral administration 50–170 mg 3 4. 3 cases
Needle site irritation Mitchell, 199934; and Oshima et al., 199040 Subcutaneous infusion 60–360 mg/24 hrs; and
subcutaneous infusion 200 mg/24 h
Angina Ward et al., 200356 Subcutaneous infusion of ketamine 150 mg/24 h
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associated with high pain scores or high opioid requirements.
This finding was also reported by the most recent Cochrane
review.14
One review that focused on ketamine for persistent post-
surgical pain30 did not find an overall reduced risk of developing
chronic postoperative pain in the ketamine group compared with
placebo. However, when exclusively IV ketamine studies were
analysed, they demonstrated statistically significant risk reduction
at 3 and 6months. According to the authors, this could have been
due to spinal NMDA receptors playing only a minor role as targets
for ketamine in postoperative pain, or due to ketamine having
lower systemic efficacy when it is administered by the epidural
route.
Most systematic reviews report that perioperative ketamine
was well tolerated, with adverse effects being mild or absent.
Most studies provided dichotomous data on central nervous
system adverse events.14
2.1.1. Clinical considerations
Although most trials investigated ketamine given by the IV route,
clinical regimens differed, especially regarding dose. Data from
the review by Brinck et al.14 indicate that 77 of the 130 trials used
racemic ketamine as an IV bolus, with 35 of these studies using
a dose less than 0.25 mg/kg. Twenty-one studies used a bolus
dose of 0.5 to 1mg/kg. Forty-two trials used racemic ketamine as
a continuous IV infusion, with themost common dose being 2 to 5
mg/kg/min. Ten trials used S(1) ketamine, of these 8 used
a preincisional IV bolus (0.075–0.5 mg/kg), followed by an IV
infusion (0.25–6.7mg/kg/min). One trial usedR(2) ketamine as an
IV bolus (1 mg/kg).
Ketamine seems most beneficial when pain scores are high,
suggesting that it is primarily useful for surgery associated with
high levels of postoperative pain. Given that ketamine reduces
opioid requirements, it may also be indicated for subgroups such
as opioid tolerant or opioid-dependent patients.
3. Ketamine for opioid-resistant pain in
palliative care
Ketamine is widely used as a third-line drug for cancer pain, when
the pain has not responded to opioid in combination with drugs
such as nonsteroidal anti-inflammatory drugs, amitriptyline, and
gabapentinoids. Published case reports demonstrate that ket-
amine is used for refractory pain in palliative care in many
countries, and that treatment regimens differ widely using IV,
subcutaneous, oral, intrathecal, and topical routes of adminis-
tration. A Cochrane review on ketamine as an adjuvant to opioid
for cancer pain,9 first published in 2003, described 32 case
reports involving 246 patients treated with ketamine. Doses
ranged from 1 mg/kg/d as a subcutaneous infusion, to 600 mg/
d as an IV infusion and 67.2 mg/d intrathecally.
3.1. Evidence for efficacy and adverse effects
A simple search of PubMed using the terms “ketamine” AND
“cancer” and the filter “systematic reviews” yielded 14 hits, 4 of
which were systematic reviews on ketamine for cancer pain. Three
of the 4 titles were different versions of the Cochrane review on
ketamine as an adjuvant to opioid in cancer pain in adults, which
hasbeen twice updated,most recently in 2017.9 The fourth titlewas
a comprehensive review of all available English language literature
on ketamine for cancer pain in children and adults13 (Table 4).
The recently updated Cochrane review included 3 RCTs. Two
small cross-over trials investigated IV ketamine in 2 doses31 or
intrathecal ketamine58 as an adjuvant to morphine. Both trials
found that ketamine reduced pain intensity and morphine
requirements. A third larger trial with a parallel-group design and
185 participants investigated rapid titration of subcutaneous
ketamine to high dose (500 mg) in participants who were using
different opioids.18 In this trial, there was no difference between
groups regarding patient-reported pain intensity, and there was
almost twice the incidence of adverse effects in the ketamine
group. Two serious adverse events (bradyarrhythmia and
cardiac arrest) believed to be related to ketamine were reported
in this trial. The update concluded that current evidence is
insufficient to assess the benefits and harms of ketamine as an
adjuvant to opioids for refractory cancer pain, and that rapid
dose escalation of ketamine to high dose (500 mg) does not
seem to have clinical benefit andmay be associatedwith serious
adverse events.
The review by Bredlau et al.,13 which used a comprehensive
approach and less stringent methodology than the Cochrane
review included 5 RCTs and 6 prospective uncontrolled trials on
Table 2
Adverse effects of ketamine, other than psychotomimetic, reported in chronic noncancer pain management.
Adverse effect Authors Comments
Urotoxicity Grégoire et al., 200817 CRPS-1. Oral ketamine titrated to 8 mg/kg/d.
Urological symptoms (dysuria, frequency, urgency,
and incontinence) noted after 9 d of treatment.
Symptoms decreased when ketamine reduced to 6
mg/kg/d, disappeared at dose of 2 mg/kg/d, but
reappeared when dose increased to 5 mg/kg/d
Hypertension Van Hecke et al., 201452 Chronic back pain. Oral ketamine, initially 20 mg3
4, increased to 20 1 20 1 20 1 30 mg daily.
Reduction in ketamine dose led to reduction in
blood pressure
Hepatotoxicity Noppers et al., 201138 CRPS-1. One or 2 continuous intravenous 100-h
S(1)-ketamine infusions (infusion rate 10–20 mg/h),
with a 16-d interval between infusions
Anosmia Mayell et al., 200929 Chronic pelvic/abdominal pain after surgery and
radiotherapy. Intranasal ketamine. Dose: 14 mg per
spray, up to 4 sprays 4 hourly, as required
Dependency Bonnet, 201512 See supplemental digital content 2, http://links.
lww.com/PR9/A26.
CRPS, complex regional pain syndrome.
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ketamine for cancer pain in adults. No RCTs in children were
identified, but the authors considered 5 retrospective studies. The
review found that ketamine reduced opioid requirements, and
may improve pain control, at the same time noting the significant
limitations of the current evidence and the wide variation in
dosages, routes, duration, and frequency of ketamine adminis-
tration in the published literature. The authors also expressed
concerns regarding ketamine’s neurotoxic effects, recommend-
ing that intrathecal administration and epidural administration
should be avoided. The review concludes that “In children and
adults with cancer pain that has not responded adequately to
standard therapy, the literature supports considering ketamine as
an adjuvant therapy.”
Several reports have described neurotoxicity when ketamine
was administered intrathecally in the palliative care setting.20,48,54
Abrupt cessation of a continuous subcutaneous infusion was
reported to result in generalized hyperalgesia.34 Storr et al.
reported 3 patients treated by a palliative care team who
developed urological symptoms (frequency, haematuria, dysuria,
and bladder pain) after oral ketamine.47 For reports of adverse
effects of ketamine, other than psychotomimetic, in the
management of refractory cancer pain, see Table 1.
Table 3
Systematic reviews of ketamine for postoperative pain.
Type of surgery Authors No. of RCTs/
participants (N)
Outcomes Comments
All Brinck et al., 201814 130, N 5 8341 Postoperative opioid consumption; pain
intensity; time to first analgesic request;
hyperalgesia; and adverse effects
IV ketamine. Cochrane review
Spinal Pendi et al., 201842 14, N 5 649 Postoperative opioid consumption; and pain
intensity
Searched for all routes of administration, but
all included studies used IV ketamine
Laparoscopic
cholecystectomy
Zhu et al., 201863 6, N 5 294 Pain intensity; postoperative opioid
consumption; length of stay; and adverse
effects
IV ketamine
Thoracotomy Moyse et al., 201736 15, N 5 360 Postoperative opioid consumption; pain
intensity; and adverse effects
IV, IM, and ED ketamine
Laparoscopic
cholecystectomy
Ye et al., 201761 5, N 5 212 Pain intensity; postoperative opioid
consumption; and adverse effects
IV ketamine
All Assouline et al., 20164 19, N 5 1453 (1349
adults
and 104 children)
Percent decrease in cumulative 24-h
morphine consumption; pain intensity;
PONV; and respiratory adverse effects
IV ketamine added to an opioid in a PCA
device
All Wang et al., 201655 36, N 5 2502 Pain intensity; cumulative morphine
consumption; patient satisfaction; PONV;
and adverse effects
IV ketamine added to PCA containing
morphine or hydromorphone
All McNicol et al., 201430 17, N 5 1800 Prevalence of PPSP; intensity or severity of
PPSP; and adverse effects
Ketamine given by any route
All Yang et al., 201459 5, N 5 266 Pain intensity; postoperative morphine
consumption; time to first analgesic; and
adverse effects
Ketamine given preoperatively
All Laskowski et al., 201121 70, N 5 4701 Total postoperative opioid consumption pain
intensity; time to first analgesic; and adverse
effects
IV ketamine. Included trials performed in
children
All Bell et al.*, 20068 37, N 5 2240 Postoperative PCA opioid consumption; pain
intensity; rescue medication; time to first
analgesic request; and adverse effects
Ketamine by any route or added to a PCA
device. Cochrane review*
All Elia et al., 200516 53, N 5 2839 Pain intensity; cumulative morphine
consumption; time to first analgesic request;
and adverse effects
Ketamine by any route or added to a PCA
device. Included trials performed in children
* Cochrane review by Bell et al.8 not updated since 2006, therefore marked “Withdrawn” in Cochrane Library.
ED, epidural; IM, intramuscular; IV, intravenous; PCA, patient-controlled analgesia; PONV, postoperative nausea and vomiting; PPSP, persistent postsurgical pain; RCT, randomized controlled trial.
Table 4
Systematic reviews on ketamine for refractory cancer pain.
Pain condition Authors No. of trials/
participants
Outcomes Comments
Cancer pain Bell et al., 20179 3, N 5 215 Patient-reported pain intensity; total opioid
consumption; rescue medication; adverse events;
patient satisfaction/preference; function; and
distress
Included only randomized, double-blinded,
placebo-controlled trials addressing ketamine given
by any route and in any dose as adjuvant to
preexisting opioid
Cancer pain Bredlau et al., 201313 16, N 5 483 adult
participants
Aimed to provide a synthesis of the data on
ketamine for refractory cancer pain in children and
adults, including dose, route of administration,
duration of treatment, effect, and adverse effects
Included 5 RCTs and 6 prospective, uncontrolled
trials in adults. No RCTs in children were identified,
but 5 retrospective studies were reviewed
RCT, randomized controlled trial.
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3.1.1. Clinical considerations
We concur with the review by Bredlau et al.13 that although the
evidence is limited, ketaminemay be useful as a third-line drug for
selected patients with refractory cancer pain. Many of the case
studies describe a dramatic effect of ketamine, but as yet, we are
unable to identify characteristics of responders. The choice of
opioid may be of importance because recent animal studies have
shown that ketamine and norketamine attenuate morphine
tolerance more effectively than oxycodone tolerance.25
There seem to be good arguments for keeping the ketamine
dose low. Ketamine has dose-dependent adverse effects.
Terminally ill cancer patients may have reduced hepatic function
because of metastases and diminished liver perfusion. Hepatic
impairment can cause reduced drugmetabolism and significantly
impaired clearance.37 Increased age has also been shown to be
associated with substantially reduced ketamine clearance.23
Examples of low-dose regimens adjuvant to opioid, primarily
morphine, are racemic ketamine 1 mg/kg/24 hours per day,7 or
S(1) ketamine (0.5–2 mg/kg/24 hours) as an IV infusion, with
careful individual titration.10
The evidence for efficacy and tolerability for ketamine in this
setting is limited. It is undeniably challenging to conduct RCTs in
this patient group.What then in theory could be the indications for
ketamine treatment? When cancer pain or pain in a palliative care
patient is refractory to opioid and adjuvant drugs, then ketamine
may be an option. There are many reasons for pain in this patient
group. Ketamine could be especially relevant when there are
problems of opioid tolerance, a significant neuropathic pain
component, inflammatory pain, depression, or any combination
of these factors. In fact, this may be the pain patient group that is
most likely to need a trial of ketamine and where the risk benefit
ratio is the most beneficial. A trial of ketamine does not need to be
lengthy and if there is no clear benefit, then ketamine treatment
should be terminated.
4. Ketamine for chronic noncancer pain
It is more difficult to formulate clear indications for the use of
ketamine in chronic noncancer pain. Given ketamine’s range of
adverse effects and the lack of safety data concerning long-term
treatment, there is good reason to be cautious when treating
complex chronic pain problems with this drug. Possible
indications could be refractory neuropathic or inflammatory pain
with, or without, depression in carefully selected patients.
Ketamine is increasingly being used as a third-line drug for
refractory chronic noncancer pain. In this setting, it is commonly
administered as intermittent IV infusions. Patients may be offered
hospital admission and infusion treatment over several days.
However, outpatient treatment seems to be on the increase, and in
the United States, a large number of “ketamine clinics” have been
established offering infusions for a variety of conditions, including
chronic pain, depression, and other mood disorders. A Medscape
report suggests that there may be more than 1000 such clinics
currently operating in the United States.51 For chronic pain, these
clinics offer a series of infusions on an outpatient basis, followed by
“maintenance therapy” for example, involving monthly ketamine
infusions.5 Although racemic ketamine is an inexpensive drug,
patient costs associatedwith this treatment are high (supplemental
digital content 1, http://links.lww.com/PR9/A25).5
4.1. Evidence for efficacy and adverse effects
A search of PubMed on February 23, 2018, using the terms
“ketamine” AND “chronic pain” and the filter “systematic reviews”
yielded 20 hits, of which 4 were systematic reviews on ketamine
for chronic noncancer pain in adults6,19,32,61 (Table 5).
Of the 2 reviews published in 2018, Michelet et al.32 included
only randomized, placebo-controlled, double-blinded trials on
ketamine for chronic pain in adults (Table 6). The authors found
low-level evidence (GRADE) demonstrating that ketamine was
ineffective regarding the primary outcome of the review, failing to
decrease pain intensity at 4 weeks after the beginning of
treatment. When only trials not judged to have a high risk of bias
were analyzed, they found moderate-level evidence that ket-
amine was effective at 4 weeks after treatment, suggesting
a long-lasting effect. However, the clinical implications of this
finding are uncertain because trial sequential analysis found the
meta-analysis to be underpowered and methodological short-
comings in several of the included trials have been noted. The
authors judged the trials by Mitchell et al.35 and Amr3 to be at high
risk of bias, whereas the methodology and conclusions of the trial
by Schwartzman et al.,44 which was prematurely terminated
before even half of the planned number of patients had been
included, have also been challenged.11 The carefully performed
trial by Sigtermans et al.45 found that ketamine infusions gave
pain relief for patients with complex regional pain syndrome
(CRPS) type I but did not result in functional improvement. As the
authors pointed out, blinding in this trial was possibly compro-
mised by ketamine-related adverse effects. Follow-up times in
these chronic pain RCTs were 1 week,53 9 days,35 11 weeks,45
and 3 months.43,44
Ketamine was generally associated with more adverse effects
than placebo. The studies were heterogenous regarding dose,
route of administration, and duration of treatment, and the
authors of the review were unable to recommend any treatment
regimen, noting the need for further trials.
Table 5
Systematic reviews of ketamine for chronic noncancer pain.





Michelet et al., 201832 6, N 5 149 Pain intensity; and adverse effects Included only randomized and placebo-controlled
trials (Table 6).
CRPS Zhao et al., 201861 15, N 5 258 Pain intensity; and percentage participants
achieving 30% or higher pain relief
One RCT. Included cohort/retrospective studies
CRPS Azari et al., 20126 19, N 5 NA Efficacy and safety Included 3 randomized, placebo-controlled trials,
7 observational studies, and 9 case reports
Chronic noncancer
pain
Hocking et al., 200319 24 published
reports,
N 5 198
No clearly defined outcomes Assessment of all published evidence, including
case reports
CRPS, complex regional pain syndrome; NA, not available; RCT, randomized controlled trial.
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Zhao et al.61 addressed ketamine infusions for CRPS-I and
CRPS-II and analyzed data from 258 participants in 15 trials.
However, only one of the 15 included studies was an RCT, and
retrospective studies were also included. Fourteen of the 15
studies used S(1) ketamine infusions, whereas one used racemic
ketamine. The authors concluded that that ketaminemay provide
short-term pain relief, but that further studies are required to
confirm this conclusion.
4.1.1. Clinical considerations
Sigtermans et al.45 when discussing the lack of functional
improvement in the ketamine group speculated whether more
prolonged treatment, possibly in combinationwith physical therapy
or rehabilitation strategies, could be necessary. Combining
ketamine treatment with rehabilitation strategies is an important
aspect, which as yet, has not been addressed by any RCT.
The addiction literature contains numerous reports on the
neurotoxic, hepatotoxic, and urotoxic adverse effects of ket-
amine. There are also case reports concerning similar ketamine-
related adverse effects in patients with chronic pain (Table 2).
Grégoire et al.17 described cystitis in a 16-year-old patient treated
for CRPS-I with oral ketamine. A patient with chronic back pain
developed uncontrolled hypertension (blood pressure 224/
124mmHg), 1 week after starting treatment with oral ketamine.52
Noppers et al.38 described 3 of 6 CRPS-I patients treated with
ketamine who developed hepatotoxicity after S(1)-ketamine
infusions. A patient with chronic pain after cancer therapy and
with no detected recurrence who received treatment with
intranasal ketamine developed permanent anosmia 6 months
after starting treatment.29
Liu et al.27 have recently reported ketamine-related upper
gastrointestinal (GI) tract toxicity, such as epigastric pain
(“K-cramps,” “K-belly”), vomiting, anaemia, and GI bleeding, in
25% of inhalational abusers of ketamine seeking treatment for
urotoxicity, and advise that young patients presenting with upper
GI symptoms should be questioned about the recreational use of
ketamine. It is not common knowledge that repeated adminis-
tration of ketamine may cause GI symptoms. Whether such
symptoms could arise in relation to repeated infusions of
ketamine is unknown, but there is a possibility that ketamine-
related GI toxicity could be overlooked in the clinical setting.
Ketamine’s potential for addiction should also be considered
when patients are treated with intermittent IV infusions. Ketamine
is a popular club drug. In animal models, repeated administration
in subanaesthetic doses causes sensitisation, a characteristic of
drugs such as cocaine. Trujillo found the results of his rodent
studies to be sufficiently concerning as to advise caution
regarding the repeated use of ketamine, both recreationally and
in the clinical setting.50 Bonnet12 report a patient initially treated
for back pain and recurrent depression who subsequently
abused and developed an addiction to ketamine (supplemental
digital content 2, http://links.lww.com/PR9/A26).
Because ketamine’s adverse effects are dose-dependent,
high doses should be avoided. Adding a low dose of ketamine to
an opioid, especially morphine, seems to improve pain relief.
However, combination treatment with potentially addictive drugs
such as ketamine and opioid in a patient group with normal life
expectancy and where treatment may be long term or repeated
multiple times may cause problems in susceptible individuals.
5. Conclusions
Ketamine is a drugwith complexmechanisms of action andmany
properties which make it interesting for pain management.
However, treatment regimens differ widely and there are
Table 6
Randomized, placebo-controlled, double-blinded trials on ketamine for chronic pain in adults (Michelet et al., 201832).
Condition Authors No. of
participants
Outcomes Comments
Neuropathic pain secondary to spinal
cord injury
Amr, 20103 40 Pain intensity; and adverse effects Ketamine infusion as an adjuvant to oral
gabapentin




35 (28 completed the
study)
BPI; total opioid requirements past 24 h;
and sensory changes
Single IV infusion of low-dose ketamine
(0.6 mg/kg over 4 h). Thirty-three
patients treated with morphine, 2 with
dextropropoxyphene.
7 withdrawals, 5 due to a surgical
procedure, and 2 due to an acute medical
event
Neuropathic pain Rigo et al., 201743 42 Pain intensity Oral ketamine 30 mg 3 3 vs oral
methadone 3 mg 3 3 vs (oral ketamine
30 mg 1 oral methadone 3 mg) 3 3




19 Overall pain level (NRS); activity; QoL; and
sensory changes
4-h IV infusion of racemic ketamine daily
for 10 d. Maximum 0.35 mg/kg/h, not to
exceed 25 mg/h (100 mg of ketamine
over a 4-h period). “CRPS medications”
continued
CRPS-I Sigtermans et al.,
200945
60 Pain intensity; sensibility; and function S(1) ketamine 4.2-d IV infusion, 1.2 mg/
kg/min (or 5 mg/h for a 70-kg patient),
titrated at regular intervals to a maximum
of 7.2mg/kg/min (or 30 mg/h for a 70-kg
patient). Participants using strong opioids
were excluded from the study.
Central pain Vranken et al., 200553 33 Pain relief; health status; and QoL Iontophoretic S(1) ketamine 50 and 75
mg.
30% of participants were using strong
opioids
BPI, Brief Pain Inventory; CRPS, complex regional pain syndrome; IV, intravenous; NRS, numeric rating scale; QoL, quality of life.
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concerns regarding adverse effects. High doses of ketamine are
reported to cause a range of adverse effects and should be
avoided. Ketamine has low oral availability, and oral administra-
tion seems to be associated with a high rate of adverse effects.
Spinal and epidural routes are not recommended because of
issues of neurotoxicity. Although ketamine is a drug of addiction,
safety data regarding long-term and/or intermittent treatment are
lacking.
There is good evidence that ketamine in the perioperative setting
reduces pain scores and opioid requirements. Adverse effects are
mild or absent, and perioperative ketamine may decrease post-
operative nausea and vomiting. It seemsmostbeneficial for surgery
associated with high levels of postoperative pain.
The evidence for the use of ketamine in palliative care is limited,
and it is not possible to recommend any specific treatment
regimen. However, despite the limited evidence, a trial of low-
dose ketamine, adjuvant to opioid (morphine), may be warranted
in refractory cancer pain or pain in palliative care.
The evidence regarding ketamine for chronic noncancer pain is
extremely limited, and there is a lack of safety data concerning
long-term or repeated treatments. Importantly, there seems to be
no strong evidence for the current widespread use of intermittent
ketamine infusions.
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[17] Grégoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-
associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C,
Dickson B, et al: ketamine-associated ulcerative cystitis: a new clinical
entity. Urology 69:810–812, 2007). Urology 2008;71:1232–3.
[18] Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt
O, Rowett D, Currow DC. Randomized, double-blind, placebo-controlled
study to assess the efficacy and toxicity of subcutaneous ketamine in the
management of cancer pain. J Clin Oncol 2012;30:3611–17.
[19] Hocking G, Cousins MJ. Ketamine in chronic pain management: an
evidence-based review. Anesth Analg 2003;97:1730–39.
[20] Karpinski N, Dunn J, Hansen L, Masliah E. Subpial vacuolar myelopathy
after intrathecal ketamine: report of a case. PAIN 1997;73:103–5.
[21] LaskowskiK,StirlingA,McKayWP,LimHJ.Asystematic reviewof intravenous
ketamine for postoperative analgesia. Can J Anaesth 2011;58:911–23.
[22] Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The
role of ketamine in preventing fentanyl-induced hyperalgesia and
subsequent acute morphine tolerance. Anesth Analg 2002;94:1263–69.
[23] Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller
JK, Hutchinson MR, Currow DC, Somogyi AA. CYP2B6*6 allele and age
substantially reduce steady-state ketamine clearance in chronic pain
patients: impact on adverse effects. Br J Clin Pharmacol 2015;80:
276–84.
[24] Lilius TO, Jokinen V, Neuvonen MS, Niemi M, Kalso EA, Rauhala PV.
Ketamine coadministration attenuates morphine tolerance and leads to
increased brain concentrations of both drugs in the rat. Br J Pharmacol
2015;172:2799–813.
[25] Lilius T, Kangas E, Niemi M, Rauhala P, Kalso E. Ketamine and
norketamine attenuate oxycodone tolerance markedly less than that of
morphine: from behaviour to drug availability. Br J Anaesth 2018;120:
818–26.
[26] Lilius TO, Viisanen H, Jokinen V, Niemi M, Kalso EA, Rauhala PV.
Interactions of (2S,6S;2R,6R)-hydroxynorketamine, a secondary
metabolite of (R,S)-ketamine, with morphine. Basic Clin Pharmacol
Toxicol 2018;122:481–88.
[27] Liu SYW, Ng SKK, TamYH, Yee SCH, Lai FPT, HongCYL, Chiu PWY, Ng
EKW, Ng CF. Clinical pattern and prevalence of upper gastrointestinal
toxicity in patients abusing ketamine. J Dig Dis 2017;18:504–10.
[28] Lu W, Wang L, Wo C, Yao J. Ketamine attenuates osteoarthritis of the
knee via modulation of inflammatory responses in a rabbit model. Mol
Med Rep 2016;13:5013–20.
[29] Mayell A, Natusch D. Anosmia–a potential complication of intranasal
ketamine. Anaesthesia 2009;64:457–58.
[30] McNicol ED, Schumann R, Haroutounian S. A systematic review and
meta-analysis of ketamine for the prevention of persistent post-surgical
pain. Acta Anaesthesiol Scand 2014;58:1199–213.
[31] Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of
intravenous ketamine in cancer patients on morphine therapy:
a randomized, controlled, double-blind, crossover, double-dose study.
J Pain Symptom Manage 2000;20:246–52.
[32] Michelet D, Brasher C, Horlin AL, Bellon M, Julien-Marsollier F, Vacher T,
Pontone S, Dahmani S. Ketamine for chronic non-cancer pain: a meta-
analysis and trial sequential analysis of randomized controlled trials. Eur J
Pain 2018;22:632–46.
[33] Mion G, Villevieille T. Ketamine pharmacology: an update
(pharmacodynamics and molecular aspects, recent findings). CNS
Neurosci Ther 2013;19:370–80.
[34] Mitchell AC. Generalized hyperalgesia and allodynia following abrupt
cessation of subcutaneous ketamine infusion. Palliat Med 1999;13:
427–28.
3 (2018) e674 www.painreportsonline.com 7
[35] Mitchell AC, Fallon MT. A single infusion of intravenous ketamine
improves pain relief in patients with critical limb ischaemia: results of
a double blind randomised controlled trial. PAIN 2002;97:275–81.
[36] Moyse DW, Kaye AD, Diaz JH, Qadri MY, Lindsay D, Pyati S.
Perioperative ketamine administration for thoracotomy pain. Pain
Physician 2017;20:173–84.
[37] Murphy EJ. Acute pain management pharmacology for the patient with
concurrent renal or hepatic disease. Anaesth Intensive Care 2005;33:
311–22.
[38] Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A,
Sarton EY. Drug-induced liver injury following a repeated course of
ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3
cases. PAIN 2011;152:2173–78.
[39] Olofsen E, Noppers I, NiestersM, Kharasch E, Aarts L, Sarton E, Dahan A.
Estimation of the contribution of norketamine to ketamine-induced acute
pain relief and neurocognitive impairment in healthy volunteers.
Anesthesiology 2012;117:353–64.
[40] Oshima E, Tei K, Kayazawa H, Urabe N. Continuous subcutaneous
injection of ketamine for cancer pain. Can J Anaesth 1990;37:385–6.
[41] PeltoniemiMA, Hagelberg NM,Olkkola KT, Saari TI. Ketamine: a review of
clinical pharmacokinetics and pharmacodynamics in anesthesia and pain
therapy. Clin Pharmacokinet 2016;55:1059–77.
[42] Pendi A, Field R, Farhan SD, Eichler M, Bederman SS. Perioperative
ketamine for analgesia in spine surgery: a meta-analysis of randomized
controlled trials. Spine (Phila Pa 1976) 2018;43:E299–E307.
[43] Rigo FK, Trevisan G, Godoy MC, Rossato MF, Dalmolin GD, Silva MA,
Menezes MS, CaumoW, Ferreira J. Management of neuropathic chronic
pain with methadone combined with ketamine: a randomized, double
blind, active-controlled clinical trial. Pain Physician 2017;20:207–15.
[44] Schwartzman RJ, Alexander GM,Grothusen JR, Paylor T, Reichenberger
E, Perreault M. Outpatient intravenous ketamine for the treatment of
complex regional pain syndrome: a double-blind placebo controlled
study. PAIN 2009;147:107–15.
[45] Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton
EY, Dahan A. Ketamine produces effective and long-term pain relief in
patients with Complex Regional Pain Syndrome Type 1. PAIN 2009;145:
304–11.
[46] Sleigh J, Harvey M, Voss L, Denny B. Ketamine—more mechanisms of
action than just NMDA blockade. Trends Anaesth Crit Care 2014;4:
76–81.
[47] Storr TM, Quibell R. Can ketamine prescribed for pain cause damage to
the urinary tract? Palliat Med 2009;23:670–72.
[48] Stotz M, Oehen HP, Gerber H. Histological findings after long-term
infusion of intrathecal ketamine for chronic pain: a case report. J Pain
Symptom Manage 1999;18:223–28.
[49] Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by
the NMDA receptor antagonist MK-801. Science 1991;251:85–7.
[50] Trujillo KA, Zamora JJ, Warmoth KP. Increased response to ketamine
following treatment at long intervals: implications for intermittent use. Biol
Psychiatry 2008;63:178–83.
[51] US Ketamine clinics continue to mushroom with no regulation. Available
at: Medscape.com. Accessed April 1, 2018.
[52] Van Hecke O, Guthrie B. Oral ketamine analgesia in chronic pain and
problematic rise in blood pressure. BMJ Case Rep 2014;2014:
bcr2014207836.
[53] Vranken JH, DijkgraafMG, KruisMR, van Dasselaar NT, van der VegtMH.
Iontophoretic administration of S(1)-ketamine in patients with intractable
central pain: a placebo-controlled trial. PAIN 2005;118:224–31.
[54] Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH.
Neuropathological findings after continuous intrathecal administration of
S(1) ketamine for the management of neuropathic cancer pain. PAIN
2005;117:231–35.
[55] Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J. Ketamine
added to morphine or hydromorphone patient-controlled analgesia for
acute postoperative pain in adults: a systematic review andmeta-analysis
of randomized trials. Can J Anaesth 2016;63:311–25.
[56] Ward J, Standage C. Angina pain precipitated by a continuous
subcutaneous infusion of ketamine. J Pain Symptom Manage 2003;25:
6–7.
[57] Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ. Current and future issues
in the development of spinal agents for the management of pain. Curr
Neuropharmacol 2017;15:232–59.
[58] Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces
morphine requirements in patients with terminal cancer pain. Can J
Anaesth 1996;43:379–83.
[59] Yang L, Zhang J, Zhang Z, Zhang C, Zhao D, Li J. Preemptive analgesia
effects of ketamine in patients undergoing surgery. A meta-analysis. Acta
Cir Bras 2014;29:819–25.
[60] Ye F, Wu Y, Zhou C. Effect of intravenous ketamine for postoperative
analgesia in patients undergoing laparoscopic cholecystectomy: a meta-
analysis. Medicine (Baltimore) 2017;96:e9147.
[61] Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment
of complex regional pain syndrome: a systemic review andmeta-analysis.
Curr Pain Headache Rep 2018;22:12.
[62] Zhu W, Ding Z, Zhang Y, Shi J, Hashimoto K, Lu L. Risks associated with
misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull 2016;
32:557–64.
[63] Zhu J, Xie H, Zhang L, Chang L, Chen P. Efficiency and safety of ketamine
for pain relief after laparoscopic cholecystectomy: a meta-analysis from
randomized controlled trials. Int J Surg 2018;49:1–9.
8 R.F. Bell, E.A. Kalso·3 (2018) e674 PAIN Reports®
